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Abstract: Objectives: Primary Sjögren syndrome (SS) is diagnosed based on the American European
Consensus Group (AECG) criteria, but lacks specificity, not only in the involvement of salivary
glands, but also in extra-glandular involvement. Whole-body somatostatin receptor scintigraphy with
99mTc-HYNIC-TOC scintigraphy could overcome these limitations. The aims of this study were to
evaluate salivary gland uptake of 99mTc-HYNIC-TOC in untreated patients with de-novo diagnosis of
SS as compared to control subjects and as compared to conventional sialoscintigraphy with 99mTcO4−.
We also aimed to evaluate the involvement of joints. Methods: 99mTc-HYNIC-TOC was used with SS
patients and uptake in joints and salivary glands was analyzed semi-quantitatively. Patients also
underwent 99mTcO4 sialoscintigraphy. The control group that we analyzed consisted of 30 patients
with neuroendocrine tumors. Results: Fifty-two females and 10 males fully met the AECG criteria for
SS, and were included. A target background ratio (TBR) >1.18 in submandibular glands correctly
classified 93% of the patients with SS in comparison to 27% for 99mTcO4 sialoscintigraphy. The area
under the curve (ROC) analysis for TBR in submandibular glands was 0.95. In joints there was a huge
variety in uptake. The median TBR was significantly higher in salivary glands in patients with SS
compared to controls. Conclusions: 99mTc-HYNIC-TOC scintigraphy identified active inflammatory
processes not only in the salivary glands, but, unexpectedly, also in many joints in patients with
primary SS, contrary to popular belief. This technique provides an objective parameter to evaluate
the inflammation burden in salivary glands and joints and could be used to evaluate response
to treatment.
Keywords: Sjögren syndrome; 99mTc-HYNIC-TOC; somatostatin receptor scintigraphy; inflammation;
salivary glands
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1. Introduction
Sjögren syndrome (SS) is a systemic autoimmune disease that primarily affects the salivary and
lacrimal glands. It usually causes a persistent dryness of the mouth and eyes due to lymphocytic
infiltration and impairment of the exocrine glands [1,2]. The presence of circulating auto-antibodies
that evoke an autoimmune response by cytokines derived from both T and B cell lymphocytes are
thought to contribute to the inflammation and destruction of the glandular tissue [3]. Primary SS
is characterized only by the presence of these exocrinopathies, whereas in secondary Sjögren these
disorders are associated with other autoimmune diseases [1].
Primary SS has a prevalence of about 0.5% in the general population, with a female predominance
of 9:1, which is approximately similar to that of systemic lupus erythematosus (SLE) [4]. SS is
commonly included in the spectrum of connective tissue diseases and sometimes shows multisystemic
involvement with a large range of clinical and serological manifestations. Besides the disease-specific
exocrine manifestations, SS may be characterized by the involvement of the joints, skin, lung, kidneys,
and nervous system, and it is associated with the production of a variety of autoantibodies [5]. The
American–European Consensus Group (AECG) criteria, published in 2002 [6], was adopted as the gold
standard criteria in Europe and in the United States to diagnose SS. For primary SS, the presence of four
out of six items showed good sensitivity (93.5%) and specificity (94%) [7,8]. The ACR-EULAR initiative
has decided to reunite the criteria to make clinical studies and therapeutic trials comparable [9]. In this
new approach, sialoscintigraphy is not included as diagnostic criterion. As a matter of fact, although
sialoscintigraphy was considered part of the diagnostic criteria for SS for AECG, this is a technique that
lacks specificity and is not commonly used anymore [10]. Diagnosing secondary SS has not yet been
addressed by the AECG, however, in practice it is usually required to fulfill the criteria for primary SS
and to additionally fulfill the American College of Rheumatology (ACR) criteria for an established
connective tissue disease such as rheumatoid arthritis (RA), SLE, dermatomyositis, myositis, or biliary
cirrhosis [11]. Particularly in the clinical diagnostic setting where SS patients present with severe
dryness, positive autoantibodies, and positive lip biopsies, it is important to assess the extent of extra
glandular involvement for therapy decision making. Therefore, a standardized whole body imaging
technique to determine other sites of disease manifestations is highly needed. Somatostatin is a
hormone that regulates several physiological cell processes via specific receptors expressed throughout
the body, particularly by nerve cells, many neuroendocrine cells, and cells mediating inflammation
and the immune response [12]. Its physiological actions are initiated by binding to G-protein-coupled
somatostatin receptors (SSTR1–SSTR5) [13]. High expression levels of SSTRs have been observed in
tumor cells as well as neo-angiogenic and peri-tumoral vessels, epithelioid cells, proliferating synovial
vessels, and activated lymphocytes and monocytes [14]. Besides overexpression in several autoimmune
and granulomatous diseases, such as RA, SLE, Schönlein–Henoch, autoimmune uveitis, ulcerative
colitis, sarcoidosis, tuberculosis, and Crohn’s disease, SSTR overexpression is also well known in
patients with SS [15,16].
A strong interest in SSTRs as targets for in vivo diagnostic and therapeutic purposes followed
the availability of somatostatin analogues [17]. Several molecules that bind to SSTR2 and SSTR5
receptors isoforms, and with lower affinity to SSTR3 [18], have been labelled with 111Indium
(111In-octreotide19 and 111In-DTPA-D-Phe(1)-octreotide (OctreoScan®, Mallinckrodt). In order to
overcome some limitations in the use of OctreoScan®, including the high costs and suboptimal physical
features of 111In, somatostatin analogues have also been labelled with 99mTechnetium, for example
using depreotide [15]15 and 99mTc–EDDA/Tricine-HYNIC-Tyr(3)-Octreotide (99mTc-HYNIC-TOC) [19].
The latter has recently been used in clinical settings including neuroendocrine tumors (NET) and a
number of chronic inflammatory diseases [20–22], where uptake of the tracer was described not only in
the main compromised organs, but also in the salivary glands. 99mTc-HYNIC-TOC has a high affinity
for SSTR2, SSTR3, and SSTR5, and has demonstrated potential utility in the diagnostic work-up and
treatment evaluation of chronic inflammatory diseases [22]. Although the use of 99mTc-HYNIC-TOC
has been extensively described for malignancies [15] and chronic inflammatory processes including
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secondary SS [7,17], the diagnostic, prognostic, and therapeutic potential in primary SS has, to our
knowledge, not been previously addressed.
The main objective of this study was to evaluate the characteristics of 99mTcHYNIC-TOC
distribution in the salivary glands of patients with newly diagnosed SS based on a semi-quantitative
analysis. The secondary objectives were (1) to correlate our findings in the salivary glands to the
conventional sialoscintigraphy with 99mTcO4−, (2) to evaluate extra-glandular involvement of the
joints, and (3) to compare the findings in salivary glands and joints with control patients without SS
that underwent 99mTc-HYNIC-TOC scintigraphy.
2. Experimental Section
2.1. Materials and Methods
2.1.1. Study Design
We retrospectively analyzed a consecutive cohort of 62 patients with de novo diagnosis of primary
SS who underwent 99mTc-HYNIC-TOC scintigraphy at the nuclear medicine unit of Clinica Colsanitas
in Bogotá between January 2013 and November 2016. Furthermore, regarding the negative control
group, we evaluated the uptake of salivary glands uptake and joints uptake of 99mTc-HYNIC-TOC in
30 patients in whom the scan was performed for staging of NET. In order to avoid an influence on
salivary gland uptake in this control group population, only subjects with negative scans or with a
very low tumor burden (located only in the abdominal area) were chosen.
2.1.2. Radiopharmaceutical Details
99mTc-HYNIC-TOC was prepared in the radiopharmaceutical department from a commercially
available kit (Tektrotyd®, POLATOM, Otwock, Poland) in accordance with the manufacturer’s
instructions. Briefly, freshly eluted 99mTcO4− (740 MBq) in a 0.9% NaCl solution (pH 7) was added to
the vial containing HYNIC-Tyr3-Octreotide (20 µg), tricine and EDDA, mixed and incubated at 80 ◦C
for 30 min according to existing recommendations [23].
2.1.3. Imaging Procedures
99mTc-HYNIC-TOC Scintigraphy
Static planar spot view images of the whole body were performed to evaluate the involvement
of salivary glands and major and minor joints. Each spot view image was acquired for 10 min
starting 3 h after intravenous (i.v.) injection of 99mTc-HYNIC-TOC (approximately 370 MBq) using a
512 × 512 matrix. The day before the study, the patients were given oral Lugol solution to prevent the
uptake in salivary glands of free 99mTcO4− possibly released by the catabolism of 99mTc-HYNIC-TOC.
The acquisition protocol used was exactly the same as described earlier [22].
99mTcO4− Sialoscintigraphy
Functional salivary gland scintigraphy (sialoscintigraphy) was performed by i.v. injection
of 99mTcO4− (185 MBq). Images were acquired dynamically over the course of 30 min using a
128 × 128 matrix. Lemon juice (2 mL) was given 10 min afterwards in order to stimulate salivary
excretion. Time activity curves were generated to evaluate the uptake and secretion patterns.
All scintigraphic images were acquired with a double-headed gamma camera (Infinia, General
Electric, Milwaukee, WI, USA) equipped with a low energy, high-resolution collimator in accordance
with a previously described protocol [22].
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2.1.4. Image Analysis
The 99mTc-HYNIC-TOC images were analyzed by two observers (KA and JR) independently
of each other and blinded to clinical details. Analysis was performed by using a method proposed
before [21]. Briefly, for semi-quantitative analysis, the calf uptake was used as the reference background.
A small region of interest (ROI) was delineated and duplicated for each salivary gland and joint
bilaterally: shoulders, elbows, wrists, metacarpophalangeal joints, inter-phalangeal joints, knees, and
ankles. We did not consider the hips because of possible artifacts due to high bladder activity. By using
the average counts in the ROIs, we calculated a ratio to compare and analyze the findings, according to
this formula: Average counts in the ROI in each part of interest/Average counts in the calf, leading to a
target-to-background ratio (TBR).
Regarding the functional salivary gland scintigraphy, the following parameters were evaluated:
(1) uptake score = target background ratio (TBR) of sum of activity at 6–10 min in both parotid glands
before lemon juice administration (temporal region was taken as background) and at 24–28 min, after
lemon juice administration; and (2) functional score = ratio between the uptake score before and after
administration of lemon juice according to Schall et al. [24].
2.1.5. Statistical Analysis
Full descriptive analysis of the variables of interest was performed in order to comply with
the objectives of the study. Frequencies (absolute and relative) and percentages were calculated for
the qualitative variables and measures of the central tendency (mean and median) and dispersion
(standard deviation and interquartile range) together with the maximum and minimum values for the
quantitative variables. A stratified analysis of the TBRs in the control group and also in the patients
with SS was performed. The Mann–Whitney test was used to evaluate the differences in the TBRs
values in the salivary glands between control patients and SS population. A post hoc analysis revealed




Data was gathered from 62 patients with confirmed primary SS and 30 healthy control subjects.
Demographic characteristics of the population and the frequency of symptoms are summarized in
Table 1. It is remarkable how much the frequency of the symptoms and the positive laboratory tests
results that belong to AECG criteria vary. The salivary gland histopathology, the anti-SSa, and anti-Ro
were present in 77%, 62%, and 62%, respectively. Moreover, the high frequency of joint pain (87%)
as part of the symptoms which are not included as diagnostic criteria in AECG, is remarkable. The
99mTc-sialoscintigraphy was positive in 27% of patients.
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Table 1. Demographic characteristics for the total population.
Control Patients n = 30 SS Patients n = 62
n % n %
Gender, female 22 73.3 52 83.87
Age, median
(range) 58.5 64 (16–80) 48.5 48 (15–71)
12–18 years 1 3.33 1 1.61
19–40 years 1 3.33 15 24.19
41–60 years 9 30.00 34 54.84
>60 years 19 63.34 12 19.35
Dry eye * - - 60 96.77
Dry mouth * - - 60 96.77
Schirmer test * - - 49 79.03
Msg
histopathology * - - 47 75.80
Sialoscintigraphy * - - 17 27.42
Joint pain - - 54 87.10
American European Consensus Group (AECG) criteria *. Abbreviations—Msg histopathology: minor salivary
gland histopathology; SS: Sjögren syndrome.
3.2. Salivary Gland Uptake of 99mTc-HYNIC-TOC
The analysis of the TBR obtained for the salivary glands for each group of patients showed higher
values in submandibular glands in patients with primary SS with a median of 2.73 and a maximum
of 5.11. The median for control patients was 1.09. Regarding the parotid glands, the median and
maximum recorded values of TBR were 1.72 and 2.3, respectively. A significant higher TBR of the
salivary glands was found in patients with primary SS compared to the control group (p < 0.001,
Mann–Whitney test). The sensitivity/specificity of the ROC curve for the TBR in the submandibular
glands was 0.95 (CI: 0.91–0.98); we found that a TBR >1.18 in submandibular glands correctly identified
92% of the patients with primary SS.
Figure 1 highlights the differences regarding the median values of TBRs for salivary glands
between the control group and the primary SS group.
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3.3. Comparison between 99mTc-HYNIC-TOC in Salivary Glands and 99mTc-Sialoscintigraphy
When we analyzed the uptake of 99mTcO4− in sialoscintigraphy we found that only 17 patients
with primary SS (27%) showed abnormal findings vs. 60 patients (97%) who visually showed any
grade of uptake with 99mTcHYNIC-TOC. With semi-quantitative analysis, using a TBR >1.18 as cut-off
point, we found that 57 patients (92%) were identified correctly by 99mTc-HYNIC-TOC.
3.4. Joint Uptake of 99mTc-HYNIC-TOC
Table 2 shows a descriptive analysis of the TBRs for every single joint in both groups.
Table 2. TBR descriptions for joints in SS and control patients.
TBR Values for Joints in Control Patients TBR Values for Joints in SS Patients
n Median SD Min Max n Median SD Min Max
Carpus 60 1.02 0.16 0.30 1.70 124 2.92 1.09 0.33 5.50
Metcp 60 1.10 0.13 0.13 1.70 124 1.06 0.57 0.90 3.20
Intphpr 60 1.00 0.13 0.98 1.70 124 1.02 0.14 0.90 1.60
Intphd 60 1.00 0.13 0.96 1.70 124 1.02 0.10 0.90 1.20
Shoul 60 1.25 0.25 0.95 1.90 124 1.03 0.40 0.90 2.10
Knee 60 1.10 0.15 0.98 1.70 124 2.60 1.30 0.90 5.60
Ankle 60 1.02 015 0.97 1.70 124 1.00 1.00 0.90 5.30
Elbow 60 1.02 0.15 0.94 1.70 124 1.10 0.70 0.90 4.10
Abbreviations—Metcp: metacarpophalangeal; Intphpr: proximal interphalangeal joint; Intphd: distal
interphalangeal joint; Shoul: shoulder.
In patients with SS the highest values were found in the carpus, followed by the knees while the
lowest values were recorded in the distal interphalangeal joints (Figure 2).
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4. Discussion
This study evaluated, for the first time, the distribution of 99mTc-HYNIC-TOC in salivary glands
and joints in a population of patients with untreated primary SS. Since SS is an immunological
disorder that may involve also involve other organs and tissues besides the salivary glands, this
whole-body imaging technique was able to identify the involvement of the joints. For salivary glands,
this imaging modality was found to be better than sialoscintigraphy, which though is part of the AECG
criteria to diagnose PSS, nowadays it tends not to be considered as part of the diagnostic criteria.
99mTc-HYNIC-TOC could potentially replace sialoscintigraphy in the diagnostic and prognostic criteria
for evaluation of this disease.
In our population the most prevalent symptoms were keratoconjunctivitis, xerostomia, and joint
pain, which are findings frequently reported in the literature as part of a broad variety of clinical
manifestations and biological abnormalities. Moreover, it is well known that this variety in symptoms
accounts for the delay in diagnosis [25]. The frequencies of symptoms and signs observed in our
population with respect to the AECG criteria confirmed the importance of combining them for early
diagnosis. Likewise, the observed incidence of positive studies in conventional sialoscintigraphy in
our population (27%) was low in comparison to the literature. This may be caused by the fact that
the distinction between normal results and minor dysfunction is not always easy to detect and mild
glandular impairment and borderline results may be misclassified by subjective judgment. In addition,
it is possible that when diagnosis is performed during the early stages of the disease, large functional
compromise of the gland may not yet be present. Therefore, the pathophysiological process which is
mediating the disease cannot be accurately evaluated with conventional sialoscintigraphy.
To evaluate the pattern of 99mTc-HYNIC-TOC uptake, a semi-quantitative analysis was performed
with the help of TBR, using the calf as background area. Values were higher in the submandibular
glands than in the parotid glands, thus showing a more severe involvement of the submandibular
glands in our population. Surprisingly, when we compared the TBR of the submandibular glands
between primary SS patients and healthy controls, medians were close to 1 for the healthy control
patients and above 2.5 for the SS patients with statistically significant difference (p < 0.01). The ROC
analysis showed that a threshold of 1.18 allowed for correct identification in 92% of the patients.
Only two patients showed no uptake of 99mTc-HYNIC-TOC; these patients had serological and ocular
tests positive for SS with sicca symptoms. Presumably, the disease had not yet affected the salivary
glands but activated immune mechanisms were present. Given the mechanism of action of this
radiopharmaceutical our results show its ability to detect the presence of somatostatin-mediated
immune cell activation in salivary glands in patients with primary SS. The theoretical model reported
in the literature supports the usefulness of this technique: abnormal antibodies and T cell responses to
muscarinic type 3 receptors (M3R) have been conceived to be pathogenic in primary SS patients [26].
The presence of autoantibodies against M3R has been reported, suggesting that an immune reaction to
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M3R reactive T cells was detected in the generation of SS [27]. M3R-reactive T cells have been detected
in 40% of patients with SS, suggesting that the M3R immune response in SS might function as an
autoantigen recognized by autoreactive T cells [28]. Patients with SS have long been thought to suffer
from a M3R-reactive T cell type Th1 condition, which has been supported by high levels of IFN-gamma
in the serum and a predominance of Th1 over Th2 cells in the blood. Despite a number of caveats,
SS is currently conceived as a model for B cell-induced autoimmune disease [29]. It is known how
the activities of these cells are orchestrated by soluble factors of the TNF family, most notably the B
cell-activating factor (BAFF) described in the late 1990s [30]. This immunologic setting could explain
the ability of 99mTc-HYNIC-TOC to detect the inflammatory process, but also the lack of sensitivity
of sialoscintigraphy to detect the disease in SS. Although further experimental evidence is needed
to confirm this hypotheses, our results suggest that positivity to 99mTc-HYNIC-TOC may forego a
reduction of salivary function. Analyses of gene expression profiles of salivary gland tissue from SS
patients have confirmed the presence of chronic inflammation [31] and in vitro analysis suggests that
cytokines such as interleukin-1-alpha may affect the process of saliva secretion by inhibiting the release
of acetylcholine from cholinergic nerves [32]. In this pathophysiological setting of the syndrome,
where an immune-mediated inflammatory process exists, the lack of correlation between the two
radiopharmaceuticals is not surprising. While 99mTc-HYNIC-TOC binds to activated lymphocytes and
provides information about disease activity, 99mTcO4− evaluates the functional impairment of glandular
parenchyma. Furthermore, although noninvasive imaging techniques such as ultrasonography (US),
CT, and MR [33] are being studied and might prove useful in the evaluation of the oral involvement
in SS, US was demonstrated to have a high diagnostic accuracy in identifying structural changes in
salivary glands [34] .We believe that 99mTc-HYNIC-TOC scintigraphy could have an added value since
it is capable to demonstrate active inflammatory processes in salivary glands secondary to SS, and
could potentially be used for therapy follow-up as well.
The evaluation of the ratios at the level of the joints in SS patients showed that higher median
values were recorded in the carpus and knees. When the medians for the different joints of the SS
patients and healthy subjects were compared, a significant difference between the two groups was
found, with healthy patients having medians close to 1 and SS patients above 2 in knees and carpus.
This finding could also support the theory that somatostatin receptors can be overexpressed in the
active phases of the diseases characterized by endothelial activation and lymphocyte infiltration of the
synovial cells [35,36]. Moreover, we already demonstrated in a pilot study in a RA population how
all patients who showed positive findings in joints at the baseline 99mTc-HYNIC-TOC scan improved
after infliximab therapy [22]. We have also suggested how this molecule is able to identify patients
with active disease responding to anti TNF-α therapy. We could not establish a cut-off in the ratios to
describe abnormality in the joints. 99mTcHYNIC-TOC can identify inflamed joints in patients with SS
since this is a disease in which the same immunological process at the level of the salivary glands can
also be observed around the epithelial structures of other organs including the liver, kidneys, and lungs.
Moreover, half of the patients develop extra-glandular complications including arthritis, interstitial
lung disease, nervous system involvement, or tubular nephropathy [37].
We found as limitation a source of confusion bias because we did not control the confounders for
the control group (age, gender among others). The analysis of the salivary glands using the planar
technique seems to underestimate their appearance and, therefore, SPECT/CT should be the technique
of choice for future studies.
One of the strongest points of our study is that our results were obtained by highly trained
rheumatologist and nuclear medicine physicians who used highly controlled and standardized methods
to evaluate the patients and to decrease the index test bias. We included a representative sample size
and used a strict type of evaluation to determine the true-positive SS patients.
As we know that PET tracers have several advantages over SPECT tracers (better resolution,
possibility for absolute quantification) we believe that 68Ga-labelled somatostatin receptor scintigraphy
will eventually replace the radiopharmaceutical we used in this study. Nevertheless, our findings
J. Clin. Med. 2019, 8, 763 9 of 11
are still important because the behavior of the 68Ga-labelled compound will be the same as the
99mTc-labelled radiopharmaceutical.
5. Conclusions
In conclusion, we showed that 99mTc-HYNIC-TOC is an important imaging technique to study SS
patients, since it allows us to identify active inflammatory processes not only in the salivary glands,
but also in the joints. More studies are required in order to include this imaging modality as part of
the diagnostic workout of patients with suspected SS to better define disease activity and the extent
of extra-glandular inflammation. Moreover, it may provide an objective parameter to evaluate the
response to treatment.
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